PFE Stock Price Quote
All of this means that Pfizer should be in the middle of a new era of growth 10 years from now. So, today, when the shares are down, is the perfect time to get in on this promising long-term story. The acquisitions of clinical-stage companies also could offer power trend growth — if acquired pipeline candidates reach the finish line. Pfizer’s pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective. Reuters highlighted that GSK emphasized that its patents underpin the technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines. The company was willing to license these patents under reasonable terms to ensure ongoing vaccine access.
- Sure, it will take a few years for Pfizer’s growth to fully kick in.
- A valuation multiple slightly lower than its historical average seems justified, in our view.
- Prosper Junior Bakiny has no position in any of the stocks mentioned.
Coronavirus product peak sales of $55 billion
This speaks volumes about Pfizer’s innovative potential and the work it was able to accomplish thanks to its success in the coronavirus market. Pfizer estimates that all of its losses of exclusivity will shave $17 billion from revenue in the period of 2025 to 2030. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Profitability
You will find other valuable comparisons for companies across industries at Peer Comparisons. Based on savvy rules of investing, PFE stock isn’t a buy right now. Shares of Pfizer have a Composite Rating of 19 out of a best-possible 99. The measure weighs a stock’s key growth metrics against all other stocks. Leading stocks tend to have Composite Ratings of 95 or better, according to IBD Digital.
We think that a slight decline in valuation multiple is justified, given the significant decline in sales. Also, the Seagen acquisition has led to a significant 2x rise in the company’s debt levels to $72 billion, compared to $36 billion in 2022. Furthermore, the company is facing increased competition for its blockbuster vaccine – Prevnar – which saw its sales growth slow to 1.6% last year versus 20.2% growth in 2022. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
As of Aug. 9, 2021, Pfizer had 5,606,688,356 shares of voting common stock outstanding. Yes, Pfizer pays a regular quarterly cash dividend of $0.39 per share. In 2020, Pfizer co-developed with BioNTech SE a vaccine against COVID-19, the virus whose rapid spread prompted the World Health Organization (WHO) to declare a global pandemic in March 2020. On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older. On May 10, 2021, the FDA expanded the EUA for the Pfizer-BioNTech vaccine to include adolescents ages 12–15.
We estimate Pfizer’s Valuation to be $29 per share, reflecting a 15% upside from the current market price of $25. PFE stock currently trades at 12x forward expected earnings of $2.14 per share in 2024, lower than its 15x average over the last five years. However, the valuation multiple has fluctuated in a wide range in recent years due to a strong earnings growth during the Covid-19 pandemic phase, driven by its vaccine and antiviral therapy. A valuation multiple slightly lower than its historical average seems justified, in our view. Pfizer’s revenue of $14.2 billion in Q4 was down 42% y-o-y, primarily due to lower sales of its Covid-19 products.
Forbes reporters follow company ethical guidelines that ensure the highest quality. Is Bourla right that the younger demographic could be a big opportunity for Pfizer’s COVID-flu combo vaccine? For the same co-pay, they could potentially receive one injection that protects against flu and COVID-19. I suspect that Pfizer will, at minimum, receive a moderate sales boost from its combo vaccine.
Overall, though, Pfizer expects that the loss of exclusivity for its products losing patent protection in the coming years will reduce annual revenue by roughly $17 billion by 2030. With this looming loss of revenue combined with sinking demand for COVID-19 products, it’s understandable why many might think that Pfizer faces almost insurmountable challenges. https://forexbroker-listing.com/city-index/ Some of these deals — such as Arena — offer Pfizer pipeline candidates, representing future potential launches. Others, like Seagen, offer immediate revenue through already approved products, as well as growth potential down the road. Pfizer forecasts more than $3 billion in Seagen revenue this year, and as much as $10 billion in 2030.
Inc. (MRK), Switzerland-based Roche Holding AG (RHHBY), and Eli Lilly and Co. (LLY). Pfizer reported adjusted net income attributable to its common shareholders of $25.2 billion on $81.3 billion in annual revenue in its 2021 fiscal year (FY). If the negative impact of its COVID-19 products is factored out, Pfizer’s year-over-year operational revenue growth in 2024 should be between 8% and 10%. However, investors can’t ignore the big hole that the slumping demand for Comirnaty and Paxlovid is causing. With $44 billion in cash and $64 billion in balance sheet debt, Pfizer maintains liquidity for uncertainties.
From a valuation perspective, PFE stock looks like it is appropriately priced. We estimate Pfizer’s Valuation to be $29 per share, close to its current levels of $28. Our forecast is based on a 13x P/E multiple for PFE and expected earnings of $2.14 https://forexbroker-listing.com/ on a per-share and adjusted basis for the full year 2024. Coming to the latest quarter, we think it will be a similar trend as in the previous quarter, with Covid-19 products seeing a decline in sales, while Vyndaqel and Abrysvo gain market share.
Now, let’s get back to our question about where Pfizer will be 10 years from now. Pfizer is executing its 19 launches over a pretty short period of time; if those products perform as expected, they could meet the company’s revenue goal and continue to drive growth in the next decade. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer’s revenue reach a record level of $100 billion in 2022; the two products made up more than half of that. Albert Bourla is the pharmaceutical giant’s current chief executive officer (CEO). Pfizer is classified as a member of the S&P 500 healthcare sector and operates within the biotechnology and pharmaceutical industry.